647 related articles for article (PubMed ID: 8637717)
1. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction.
Chen IT; Akamatsu M; Smith ML; Lung FD; Duba D; Roller PP; Fornace AJ; O'Connor PM
Oncogene; 1996 Feb; 12(3):595-607. PubMed ID: 8637717
[TBL] [Abstract][Full Text] [Related]
2. p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity.
Fotedar R; Fitzgerald P; Rousselle T; Cannella D; Dorée M; Messier H; Fotedar A
Oncogene; 1996 May; 12(10):2155-64. PubMed ID: 8668341
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.
Rousseau D; Cannella D; Boulaire J; Fitzgerald P; Fotedar A; Fotedar R
Oncogene; 1999 May; 18(21):3290-302. PubMed ID: 10359535
[TBL] [Abstract][Full Text] [Related]
4. Hyperoxia induces S-phase cell-cycle arrest and p21(Cip1/Waf1)-independent Cdk2 inhibition in human carcinoma T47D-H3 cells.
Bilodeau JF; Faure R; Piedboeuf B; Mirault ME
Exp Cell Res; 2000 May; 256(2):347-57. PubMed ID: 10772807
[TBL] [Abstract][Full Text] [Related]
5. Deregulation of p53/p21Cip1/Waf1 pathway contributes to polyploidy and apoptosis of E1A+cHa-ras transformed cells after gamma-irradiation.
Bulavin DV; Tararova ND; Aksenov ND; Pospelov VA; Pospelova TV
Oncogene; 1999 Oct; 18(41):5611-9. PubMed ID: 10523840
[TBL] [Abstract][Full Text] [Related]
6. Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1.
Luo Y; Hurwitz J; Massagué J
Nature; 1995 May; 375(6527):159-61. PubMed ID: 7753174
[TBL] [Abstract][Full Text] [Related]
7. Identification of binding domains on the p21Cip1 cyclin-dependent kinase inhibitor.
Goubin F; Ducommun B
Oncogene; 1995 Jun; 10(12):2281-7. PubMed ID: 7784076
[TBL] [Abstract][Full Text] [Related]
8. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.
Orend G; Hunter T; Ruoslahti E
Oncogene; 1998 May; 16(20):2575-83. PubMed ID: 9632134
[TBL] [Abstract][Full Text] [Related]
9. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J
Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932
[TBL] [Abstract][Full Text] [Related]
10. Identification of a p130 domain mediating interactions with cyclin A/cdk 2 and cyclin E/cdk 2 complexes.
Lacy S; Whyte P
Oncogene; 1997 May; 14(20):2395-406. PubMed ID: 9188854
[TBL] [Abstract][Full Text] [Related]
11. Expression of a novel form of p21Cip1/Waf1 in UV-irradiated and transformed cells.
Poon RY; Hunter T
Oncogene; 1998 Mar; 16(10):1333-43. PubMed ID: 9546435
[TBL] [Abstract][Full Text] [Related]
12. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53.
Rao S; Lowe M; Herliczek TW; Keyomarsi K
Oncogene; 1998 Nov; 17(18):2393-402. PubMed ID: 9811471
[TBL] [Abstract][Full Text] [Related]
13. Cloning and characterization of a novel p21(Cip1/Waf1)-interacting zinc finger protein, ciz1.
Mitsui K; Matsumoto A; Ohtsuka S; Ohtsubo M; Yoshimura A
Biochem Biophys Res Commun; 1999 Oct; 264(2):457-64. PubMed ID: 10529385
[TBL] [Abstract][Full Text] [Related]
14. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway.
Rousseau D; Cannella D; Boulaire J; Fitzgerald P; Fotedar A; Fotedar R
Oncogene; 1999 Jul; 18(30):4313-25. PubMed ID: 10439039
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells.
Gong J; Ammanamanchi S; Ko TC; Brattain MG
Cancer Res; 2003 Jun; 63(12):3340-6. PubMed ID: 12810668
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21.
Li Y; Jenkins CW; Nichols MA; Xiong Y
Oncogene; 1994 Aug; 9(8):2261-8. PubMed ID: 7913544
[TBL] [Abstract][Full Text] [Related]
17. Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells.
Lu Y; Yamagishi N; Yagi T; Takebe H
Oncogene; 1998 Feb; 16(6):705-12. PubMed ID: 9488034
[TBL] [Abstract][Full Text] [Related]
18. Requirements for p53 and the ATM gene product in the regulation of G1/S and S phase checkpoints.
Xie G; Habbersett RC; Jia Y; Peterson SR; Lehnert BE; Bradbury EM; D'Anna JA
Oncogene; 1998 Feb; 16(6):721-36. PubMed ID: 9488036
[TBL] [Abstract][Full Text] [Related]
19. Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells.
Sekiguchi T; Hunter T
Oncogene; 1998 Jan; 16(3):369-80. PubMed ID: 9467962
[TBL] [Abstract][Full Text] [Related]
20. TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase.
Ono T; Kitaura H; Ugai H; Murata T; Yokoyama KK; Iguchi-Ariga SM; Ariga H
J Biol Chem; 2000 Oct; 275(40):31145-54. PubMed ID: 10878006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
